Complications of recombinant activated human coagulation factor VII.

BACKGROUND Recombinant factor VIIa (rFVIIa) frequently is used for treatment of life-threatening hemorrhage in trauma. METHODS A retrospective review of injured patients receiving rFVIIa at an American College of Surgeons-verified Level 1 trauma center was performed. Controls were matched for age, sex, Injury Severity Score, and traumatic brain injury. Thrombotic complications in patients administered rFVIIa, including deep venous thrombosis (DVT), pulmonary embolus, acute myocardial infarction, ischemic stroke, mesenteric ischemia, arterial thromboembolism, and death, were determined. RESULTS Thirty-six patients were given rFVIIa, of whom 5 (13.8%) had thrombotic complications. Indications for rFVIIa were life-threatening intracranial bleeding in the presence of pre-injury anticoagulation or hemorrhage. The incidences of DVT (n = 4) and acute myocardial infarction (n = 1) were noted. In the control group, there were fewer thrombotic complications (DVT, 1; pulmonary embolus, 1). The mortality rate (52.8%) was higher in patients receiving rFVIIa compared with the control group (22.2%; P = .014). Pre-injury anticoagulation was common in the treatment group. CONCLUSIONS Pre-injury anticoagulation is frequently the indication for rFVIIa administration. Thrombotic complications occur with rFVIIa administration. The mortality rate of injured patients who receive rFVIIa is high.

[1]  D. Thabut,et al.  Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. , 2004, Gastroenterology.

[2]  J. Oliver,et al.  Platelet activity of high‐dose factor VIIa is independent of tissue factor , 1997, British journal of haematology.

[3]  W. Bechstein,et al.  Recombinant Coagulation Factor VIIa in Major Liver Resection: A Randomized, Placebo-controlled, Double-blind Clinical Trial , 2005, Anesthesiology.

[4]  C. Kessler,et al.  Reversal of Warfarin-Induced Excessive Anticoagulation with Recombinant Human Factor VIIa Concentrate , 2002, Annals of Internal Medicine.

[5]  R. Rossaint,et al.  Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. , 2005, The Journal of trauma.

[6]  E. Segal,et al.  Recombinant activated factor VII for adjunctive hemorrhage control in trauma. , 2001, The Journal of trauma.

[7]  R. Grounds,et al.  Use of activated recombinant coagulation factor VII in patients undergoing reconstruction surgery for traumatic fracture of pelvis or pelvis and acetabulum: a double-blind, randomized, placebo-controlled trial. , 2005, British journal of anaesthesia.

[8]  T. Scalea,et al.  Thromboembolic complications associated with factor VIIa administration. , 2007, The Journal of trauma.

[9]  M. Tarantino,et al.  The use of recombinant activated factor VII to reverse warfarin-induced anticoagulation in patients with hemorrhages in the central nervous system: preliminary findings. , 2003, Journal of neurosurgery.

[10]  K. Kurth,et al.  Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial , 2003, The Lancet.

[11]  Michael D Pasquale,et al.  "Low-dose" recombinant activated factor VII results in less blood and blood product use in traumatic hemorrhage. , 2005, The Journal of trauma.

[12]  E. Erhardtsen.  Ongoing NovoSeven® trials , 2002, Intensive Care Medicine.

[13]  Po-Huang Lee,et al.  Safety and hemostatic effect of recombinant activated factor VII in cirrhotic patients undergoing partial hepatectomy: a multicenter, randomized, double-blind, placebo-controlled trial. , 2006, American journal of surgery.

[14]  J. Barletta,et al.  A review of recombinant factor VII for refractory bleeding in nonhemophilic trauma patients. , 2005, The Journal of trauma.

[15]  D. Brody,et al.  Use of recombinant factor VIIa in patients with warfarin-associated intracranial hemorrhage , 2005, Neurocritical care.

[16]  S. Mayer,et al.  Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. , 2008, The New England journal of medicine.